Clinical Quick Reference — Lipid Modification to Reduce Cardiovascular Risk
The 2019 ESC/EAS Guidelines recommend use of the SCORE2 system to estimate 10-year fatal and non-fatal atherosclerotic CVD risk for individuals without pre-existing disease. The SCORE2 model incorporates age, sex, total cholesterol, HDL-C, systolic BP, smoking status, and antihypertensive treatment to stratify patients into four risk categories.
Key Change: SCORE2 replaces SCORE (2003). SCORE2 better predicts modern risk in low- and high-risk countries; SCORE2-OP applies to those aged ≥65 years. Use online calculator at www.heartcore.org or within SattiMD tools.
10-year CVD risk <2.5%
10-year CVD risk 2.5–4.9%
10-year CVD risk 5.0–9.9%
10-year CVD risk ≥10%, or any prior CVD event, or diabetes with target organ damage
Risk Modifiers (Qualifiers): Abnormal lipids, metabolic syndrome, Lp(a) ≥180 mg/dL, family history of premature CVD, chronic inflammatory diseases, male gender, female post-menopausal status, CKD stage 3 or worse.
Calculate your patient's SCORE2 risk: Use the SCORE2 Calculator to estimate 10-year risk; for U.S. patients, consider Pooled Cohort Equations or Lifetime ASCVD Risk.
| Risk Category | SCORE2 / Definition | LDL-C Target | Non-HDL-C Goal | ApoB Goal |
|---|---|---|---|---|
| Low Risk | <2.5% | No CVD, no major risk factors | <3.0 mmol/L (116 mg/dL) | <2.2 mmol/L (85 mg/dL) | <65 mg/dL |
| Moderate Risk | 2.5–4.9% | Risk modifiers or borderline elevations | <2.6 mmol/L (100 mg/dL) | <2.2 mmol/L (85 mg/dL) | <80 mg/dL |
| High Risk | 5–9.9% | Documented CVD or multiple risk factors | <1.8 mmol/L (70 mg/dL) | <1.6 mmol/L (61 mg/dL) | <80 mg/dL |
| Very High Risk | ≥10%, or prior CVD, or DM with target organ damage, or FH with ASCVD | <1.4 mmol/L (55 mg/dL) | <1.4 mmol/L (54 mg/dL) | <100 mg/dL |
| Very High Risk (Secondary) | Prior MI, coronary/vascular procedure, acute coronary syndrome | <1.4 mmol/L (55 mg/dL), ideally <1.0 mmol/L (40 mg/dL) | <1.4 mmol/L (54 mg/dL) | <100 mg/dL |
Key Point: The lower the achieved LDL-C level, the greater the proportional risk reduction. A 1.0 mmol/L (39 mg/dL) absolute reduction in LDL-C is associated with approximately 20% relative reduction in major vascular events.
| Recommendation | Class | Evidence |
|---|---|---|
| Total cholesterol (TC) for CV risk estimation using SCORE2. | 1 | C |
| LDL-C is primary for screening, diagnosis, and management. | 1 | C |
| HDL-C for SCORE2 risk estimation (online calculator). | 1 | C |
| Triglycerides as part of routine lipid assessment, especially high-TG, obesity, or metabolic syndrome. | 1 | C |
| Non-HDL-C recommended for risk assessment, especially with elevated TGs. | 1 | C |
| ApoB analysis recommended in people with high TGs, DM, obesity, or very low LDL-C; alternative to non-HDL-C. | 1 | C |
| Lp(a) should be measured at least once in each adult's lifetime to identify very high inherited Lp(a) (>180 mg/dL). | IIa | C |
Non-fasting lipid samples are acceptable. The difference between fasting and non-fasting TGs is <0.3 mmol/L (27 mg/dL) in most individuals. Non-fasting sampling can be used in most clinical settings.
Lifestyle measures are the foundation of dyslipidemia management and should be initiated in all patients. The magnitude of effect depends on adherence and baseline risk profile.
| Intervention | Magnitude of Effect | Level of Evidence |
|---|---|---|
| Avoid dietary trans fats | Reduces TC & LDL-C by ~10% | A |
| Reduce dietary saturated fat | Reduces TC & LDL-C by ~5–10% | A |
| Increase dietary fiber (soluble) | Reduces TC & LDL-C by ~3–5% | A |
| Use plant sterols / stanols (2 g/day) | Reduces LDL-C by ~7–10% | A |
| Weight reduction (5–10% body weight loss) | Reduces TC, LDL-C, TGs; increases HDL-C | A |
| Habitual physical activity (3.5–7 h/week moderate) | Increases HDL-C; modest TG reduction | B |
| Smoking cessation | Increases HDL-C; improves CVD outcomes | A |
| Reduce alcohol intake | Reduces TGs, especially in HTG | A |
| Food Category | To Be Preferred | In Moderation | Occasionally Only |
|---|---|---|---|
| Cereals | Wholegrain | Refined bread, rice, pasta | Pastries, muffins, croissants |
| Vegetables | Raw & cooked vegetables | Potatoes | In butter or cream |
| Legumes | Lentils, beans, chickpeas, soy | — | — |
| Fruit | Fresh or frozen | Dried, jams, canned in syrup | Juices, ice cream, fructose drinks |
| Meat & Fish | Lean & oily fish, poultry | Lean cuts of beef, lamb, veal | Processed meats, sausages, bacon |
| Dairy | Skimmed milk & yogurt | Low-fat cheese | Regular cheese, cream, whole milk yogurt |
| Cooking Fats | Olive oil, unsaturated oils | Soft margarines, salad dressing | Trans fats, butter, lard, hard margarine |
Practical Targets: No smoking • Healthy diet low in saturated fat • 3.5–7 h physical activity weekly • BMI 20–25 kg/m² • Waist circumference <94 cm (men), <80 cm (women) • BP <140/90 mmHg
The treatment algorithm depends on baseline CV risk, baseline LDL-C level, and response to therapy. Start with maximum-tolerated dose of a high-intensity statin; if goals are not met, add ezetimibe; if still not achieved, add PCSK9 inhibitor.
| Statin Regimen | LDL-C Reduction (%) | Example Dosing |
|---|---|---|
| Low-intensity statin | ~15–30% | Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg |
| Moderate-intensity statin | ~30–50% | Atorvastatin 40 mg; Rosuvastatin 20 mg |
| High-intensity statin | ~50% | Atorvastatin 80 mg; Rosuvastatin 40 mg |
| High-intensity statin + ezetimibe | ~65% | Atorvastatin 80 mg + ezetimibe 10 mg |
| PCSK9 inhibitor monoclonal Ab | ~60% | Evolocumab, alirocumab |
| PCSK9i + high-intensity statin | ~75% | Evolocumab + atorvastatin 80 mg |
| PCSK9i + statin + ezetimibe | ~85% | Evolocumab + atorvastatin 80 + ezetimibe 10 mg |
Note: Absolute LDL-C reduction is what matters for risk reduction. Each 1.0 mmol/L (39 mg/dL) reduction in LDL-C is associated with ~20% relative reduction in major vascular events. Use the LDL-C Reduction Calculator to estimate on-treatment LDL-C for different drug combinations.
Mechanism: Inhibit HMG-CoA reductase, reducing cholesterol synthesis in liver & upregulating LDL receptors → increased LDL uptake & reduced plasma LDL-C. Cornerstone of dyslipidemia therapy.
Efficacy: Reduce LDL-C by 15–50%. Also reduce TGs by 10–20%; modestly increase HDL-C.
CV Benefit: Large meta-analyses show ~22% reduction in major vascular events per mmol/L LDL-C reduction. Benefits in both primary & secondary prevention.
Tolerability: Generally well-tolerated. Muscle symptoms (~10–15%), elevated liver enzymes (usually reversible), potential new-onset diabetes (~1 per 250–300 patients over 2 years).
Mechanism: Inhibits cholesterol uptake at intestinal brush border (NPC1L1), reducing cholesterol delivery to liver & upregulating LDL receptors.
Efficacy: As monotherapy: ~15–22% LDL-C reduction. Added to statin: additional 15–27% LDL-C reduction. No major effect on TGs; HDL-C may increase slightly.
CV Benefit: Benefit in major ASCVD outcomes established in combination therapy.
Tolerability: Well-tolerated. GI side effects uncommon. Safe at all statin doses. No hepatotoxicity or myopathy signal.
Mechanism: mAbs target PCSK9, a protein promoting LDL receptor degradation. Inhibiting PCSK9 keeps more LDL receptors on hepatocyte surface → dramatically increased LDL uptake.
Efficacy: Reduce LDL-C by ~50–60% when added to maximum-tolerated statin (±ezetimibe). Can achieve LDL-C <1.0 mmol/L in most patients.
Agents: Evolocumab (140 mg SC every 2 weeks or 420 mg monthly), alirocumab (75–150 mg SC every 2 weeks), inclisiran (284 mg SC at baseline, week 4, then every 6 months).
CV Benefit: FOURIER & ODYSSEY Outcomes trials showed 13–15% relative risk reduction in major CVD events. Benefits within 1–2 years in secondary prevention.
Tolerability: Generally well-tolerated. Injection-site reactions (mild). Post-marketing surveillance: neuropsychiatric concerns; clinical trials showed no excess. Monitor for cognitive changes.
Cost & Access: Expensive; often requires prior authorization. Reimbursement typically reserved for very-high-risk patients.
Fibrates: PPAR-α agonists; reduce VLDL & TG-rich remnants. Most effective for HTG (TGs >2.3 mmol/L). Limited LDL-C reduction. Combined with statins: increased myopathy risk; use with caution. Benefit in major CVD outcomes modest.
Bile Acid Sequestrants: Bind bile acids, promoting hepatic cholesterol consumption. Reduce LDL-C by ~10–20%. GI side effects (constipation, flatulence) limit use. Useful in younger patients or statin intolerance. Safe in combination with other agents.
Inclisiran (siRNA PCSK9): Reduces PCSK9 mRNA. Longer duration than mAbs (6-monthly dosing). Reduces LDL-C ~45–50%. Approvals in Europe & select countries; FDA approval pending.
Bempedoic Acid: Inhibits uric acid production & reduces inflammation. Modestly reduces LDL-C (~10%) & TGs (~10%). May increase serum urate. New agent; long-term outcome trials ongoing.
Mipomersen: Antisense oligonucleotide targeting ApoB-100 mRNA. Reduces LDL-C ~25–30% when added to statins. Limited use due to injection-site reactions & liver toxicity risk. Reserved for severe FH.
n-3 Fatty Acids (Omega-3 PUFAs): Reduce TG levels (~20–30% in high-dose trials). LDL-C may increase slightly. Mixed results in CVD outcome trials. Current guidelines do not recommend routine use unless TGs severely elevated (>5 g/day).
Nicotinic Acid (Niacin): Reduces VLDL & raises HDL-C. Side effects (flushing, GI upset, liver toxicity) limit tolerability. HPS2-THRIVE trial showed no additional benefit when added to statin + ezetimibe. Not recommended in routine practice.
Autosomal dominant condition causing premature atherosclerotic CVD due to lifelong LDL-C elevation. Prevalence: Heterozygous FH ~1 in 200–300; homozygous FH ~1 in 160,000–250,000.
| Criterion | Points |
|---|---|
| 1) Family History | |
| First-degree relative with premature CAD (men <55 yr, women <60 yr) or LDL-C >95th percentile | 1 |
| First-degree relative with tendon xanthomas or arcus cornealis, or child <18 yr with LDL-C >95th percentile | 2 |
| 2) Clinical History | |
| Premature CAD (men <55 yr, women <60 yr) | 2 |
| Premature cerebral or peripheral arterial disease | 1 |
| 3) Physical Examination | |
| Tendon xanthomas | 6 |
| Arcus cornealis before age 45 | 4 |
| 4) LDL-C Level (untreated) | |
| LDL-C ≥325 mg/dL (≥8.4 mmol/L) | 8 |
| LDL-C 251–325 mg/dL (6.5–8.4 mmol/L) | 5 |
| LDL-C 191–250 mg/dL (4.9–6.4 mmol/L) | 3 |
| LDL-C 155–190 mg/dL (4.0–4.9 mmol/L) | 1 |
| 5) DNA Analysis | |
| Functional mutation in LDL receptor, APOB, or PCSK9 | 8 |
Scoring: ≥8 points = definite FH; 6–7 points = probable FH; 3–5 points = possible FH. For suspected FH, genetic testing (LDLR, APOB, PCSK9 genes) recommended to confirm diagnosis.
| Risk Group | LDL-C Target | Recommended Treatment | Class | Level |
|---|---|---|---|---|
| FH with ASCVD or another major risk factor (very-high-risk) | <1.4 mmol/L (<55 mg/dL); ideally <1.0 mmol/L (<40 mg/dL) | High-intensity statin + ezetimibe. If goal not reached, add PCSK9 inhibitor. Consider bempedoic acid or mipomersen for extreme elevations. | 1 | C |
| Primary prevention FH, very-high-risk | <1.4 mmol/L (<55 mg/dL) | High-intensity statin + ezetimibe. PCSK9 inhibitor recommended if goal not achieved on dual therapy. | 1 | C |
| Primary prevention FH, lower risk | <2.6 mmol/L (<100 mg/dL) | Healthy lifestyle + low-dose statin initially, uptitrating cautiously; reassess annually. | IIa | C |
Patients with type 2 diabetes (T2DM) are at very high CVD risk. Type 1 diabetes (T1DM) also confers high risk, especially with microalbuminuria.
Typical pattern: Elevated TGs, reduced HDL-C, with variable LDL-C (ApoB often elevated). Small dense LDL particles predominate.
| Patient Group | LDL-C Target | Recommendation | Class | Level |
|---|---|---|---|---|
| T2DM at very-high risk (prior CVD) | <1.4 mmol/L (<55 mg/dL); consider <1.0 mmol/L after second event within 2 years | High-intensity statin (≥50% LDL-C reduction). If goal not reached, add ezetimibe; if still not achieved, add PCSK9 inhibitor. | 1 | A |
| T2DM at high or very-high risk (no prior CVD) | <1.8 mmol/L (<70 mg/dL) | Statin therapy with ≥50% LDL-C reduction. Ezetimibe should be considered if goal not reached on statin alone. | 1 | A |
| T1DM at very-high risk | <1.4 mmol/L (<55 mg/dL) | High-intensity statin with ≥50% LDL-C reduction. Combination therapy (ezetimibe, PCSK9i) if needed. | 1 | A |
| T1DM at high risk | <1.8 mmol/L (<70 mg/dL) | Statin therapy with ≥50% LDL-C reduction. Consider ezetimibe if target not achieved. | 1 | A |
Intensification: If LDL-C goal not reached on maximum-tolerated statin alone, add ezetimibe. If still not achieved, add PCSK9 inhibitor.
Pregnancy: Statins & ezetimibe NOT recommended in pregnancy or for women planning pregnancy. Bile acid sequestrants may be considered if necessary. Optimize lipid management pre-conception.
Patients with ACS are at very high risk of recurrent events. Intensive LDL-C lowering is strongly recommended, ideally starting in the first 1–4 days of hospitalization.
| Intervention | Recommendation | Class | Level |
|---|---|---|---|
| High-intensity statin | Initiate in all ACS patients on the first day of hospitalization, regardless of baseline LDL-C. Uptitrate if already on statin. | 1 | A |
| Ezetimibe | If LDL-C goal not reached 4–6 weeks after ACS on maximally tolerated statin, add ezetimibe (10 mg daily). | 1 | B |
| PCSK9 Inhibitor (Early) | If LDL-C goal not achieved after 4–6 weeks on maximum tolerated statin + ezetimibe, add PCSK9 inhibitor. Consider early PCSK9i in patients failing maximum-tolerated statin at event time. | 1 | B |
| LDL-C Target | <1.4 mmol/L (<55 mg/dL); ideally <1.0 mmol/L (<40 mg/dL). | 1 | B |
Older adults have high absolute CVD risk. Statin therapy in those <75 should proceed as in younger patients. For those ≥75, initiate at low dose if significant renal impairment, drug interactions, or high fall risk; uptitrate cautiously. Benefit in very elderly (≥85 yr) for primary prevention remains debated; individualized approach recommended.
Patients with CKD stages 3–5 are at high-to-very-high CVD risk. Lipid profile typically shows elevated TGs, low HDL-C, variable LDL-C. Lipid management recommended per KDIGO guidelines. Statins are safe & effective; ezetimibe may be added if goals not met. PCSK9 inhibitors effective but require careful monitoring in advanced CKD. Use caution with fibrates (myopathy risk); prefer statin & ezetimibe combinations. Dosing adjustments for some agents may be needed if eGFR <30 mL/min/1.73m².
Statin efficacy & CV benefits in women similar to men. Hormone therapy (estrogen-progestin) NOT recommended for lipid management or CV prevention due to adverse CV effects. Non-HDL-C may be a better risk marker in women with elevated TGs. Pregnancy: Statins & ezetimibe are contraindicated. Breastfeeding: Statin use not recommended during lactation.
Patients with ischemic stroke, TIA, or PAD are at very-high CVD risk. Intensive LDL-C lowering (<1.4 mmol/L / <55 mg/dL) recommended. High-intensity statin should be initiated early & sustained indefinitely. Statins provide consistent CV & leg symptom benefits in PAD.
Role of statins in heart failure (HF) debated. In HFrEF without prior CVD, statin initiation may not be indicated (Class III). However, patients with HF & established CAD should remain on statins. Aortic stenosis progression not slowed by statin therapy alone. Aortic sclerosis (calcification without obstruction) not slowed by statins.
Dyslipidemia very common post-transplant & increases CVD risk. Immunosuppressive drugs (calcineurin inhibitors, mTOR inhibitors) may worsen lipid profile. Statins initiated at low doses with caution due to drug–drug interactions (especially calcineurin inhibitors). Ezetimibe is a safe alternative or addition. PCSK9 inhibitors effective but require careful interaction assessment. Specialist oversight recommended.
Definitions: Borderline elevated TGs 1.5–2.3 mmol/L (135–199 mg/dL); high TGs 2.3–5.7 mmol/L (200–499 mg/dL); very high TGs ≥5.7 mmol/L (≥500 mg/dL). Very high TGs (>11 mmol/L / >1000 mg/dL) carry risk of acute pancreatitis.
| Situation | Recommendation | Class | Level |
|---|---|---|---|
| High-risk patients with TGs 1.5–5.6 mmol/L (135–499 mg/dL) despite statin | Statin treatment recommended as first drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridemia. | 1 | B |
| Persistent HTG despite max-tolerated statin; n-3 PUFAs consideration | In high- or above patients with TGs between 1.5–5.6 mmol/L despite statin treatment, n-3 PUFAs (icosapent ethyl 2–4 g/day) should be considered in combination with statins. | IIa | B |
| Primary prevention without FH, LDL-C goal <2.3 mmol/L, fenofibrate consideration | In primary prevention patients at low-risk who are LDL-C goal <2.3 mmol/L, fenofibrate or bezafibrate may be considered in combination with statins for TG lowering. | IIb | B |
| Extreme HTG (>11 mmol/L / >1000 mg/dL) | Severe restriction of calories & fat (10–15%), weight reduction, withdrawal of secondary risk factors (alcohol, estrogens), initiation of lipid-lowering therapy. Specialist referral recommended. | N/A | N/A |
Measurement: Lp(a) should be measured at least once in each adult's lifetime to identify very high inherited Lp(a) levels (>180 mg/dL or >430 nmol/L).
Risk Adjustment: For individuals at borderline moderate-to-high CV risk with very high Lp(a), consider Lp(a)-adjusted ASCVD risk. These individuals may benefit from more intensive LDL-C lowering (use Lp(a)-ASCVD risk calculator).
Treatment: Lp(a) is largely genetically determined; lifestyle modifications have minimal effect. LDL-C lowering therapies (statins, ezetimibe, PCSK9i) reduce Lp(a) modestly (~20–25% with PCSK9i mAbs). New antisense oligonucleotide approaches targeting apolipoprotein(a) directly are under investigation. Currently, no specific Lp(a)-lowering therapy is recommended in routine practice; focus remains on intensive LDL-C lowering in high Lp(a) patients.
Use these tools to support clinical decision-making: estimate cardiovascular risk, calculate expected LDL-C reduction, assess renal function, and adjust therapy.
Estimate 10-year fatal and non-fatal atherosclerotic CVD risk using the ESC SCORE2 model.
Predict expected LDL-C reduction with different statin, ezetimibe, and PCSK9 inhibitor combinations.
Adjust 10-year ASCVD risk based on elevated lipoprotein(a) levels.
Alternative 10-year ASCVD risk calculator commonly used in North America.
Estimate glomerular filtration rate from serum creatinine for medication dosing.
Alternative creatinine clearance estimation for renal dosing adjustments.
Classic 10-year coronary heart disease risk tool; useful for comparison or older populations.
Estimate lifetime (to age 95) atherosclerotic CVD risk for young and middle-aged adults.